Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7 AUG 27 USPATOLD now available on STN
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10 SEP 13 FORIS renamed to SOFIS
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13 SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16 OCT 19 BEILSTEIN updated with new compounds
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18 NOV 19 WPIX enhanced with XML display format
NEWS 19 NOV 30 ICSD reloaded with enhancements
NEWS 20 DEC 04 LINPADOCDB now available on STN

```
 NEWS 21  DEC 14  BEILSTEIN pricing structure to change
 NEWS 22  DEC 17  USPATOLD added to additional database clusters
 NEWS 23  DEC 17  IMSDRUGCONF removed from database clusters and STN
 NEWS 24  DEC 17  DGENE now includes more than 10 million sequences
 NEWS 25  DEC 17  TOXCENTER enhanced with 2008 MeSH vocabulary in
                  MEDLINE segment
 NEWS 26  DEC 17  MEDLINE and LMEDLINE updated with 2008 MeSH
vocabulary
 NEWS 27  DEC 17  CA/CAplus enhanced with new custom IPC display
formats
 NEWS 28  DEC 17  STN Viewer enhanced with full-text patent content
                  from USPATOLD

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation
of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *
* *

FILE 'HOME' ENTERED AT 20:34:59 ON 20 DEC 2007

=> File Medline EMBASE Biosis Caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.21       0.21

FILE 'MEDLINE' ENTERED AT 20:35:12 ON 20 DEC 2007

FILE 'EMBASE' ENTERED AT 20:35:12 ON 20 DEC 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 20:35:12 ON 20 DEC 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 20:35:12 ON 20 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

=> s (protease or peptidase or proteinase) (4A) (fusion protein)
L1 776 (PROTEASE OR PEPTIDASE OR PROTEINASE) (4A) (FUSION PROTEIN)

=> s (protease or peptidase or proteinase) (4A) (auto or self)
L2 571 (PROTEASE OR PEPTIDASE OR PROTEINASE) (4A) (AUTO OR SELF)

=> s (fusion protein)(4A) (auto or self)
L3 156 (FUSION PROTEIN)(4A) (AUTO OR SELF)

=> s l1 and l2 and l3
L4 5 L1 AND L2 AND L3

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):rem
ENTER L# LIST OR (END):l4
PROCESSING COMPLETED FOR L4
L5 5 DUPLICATE REM L4 (0 DUPLICATES REMOVED)

=> d l5 1-5 bib ab

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:277491 CAPLUS
DN 142:458829
TI Self-cleavage of fusion protein in vivo
using TEV protease to yield native protein
AU Shih, Yan-Ping; Wu, Hui-Chung; Hu, Su-Ming; Wang, Ting-Fang; Wang, Andrew
H.-J.
CS Institute of Biological Chemistry and National Core Facilities of High
Throughput Protein Production, Academia Sinica, Taipei, 115, Taiwan
SO Protein Science (2005), 14(4), 936-941
CODEN: PRCIEI; ISSN: 0961-8368
PB Cold Spring Harbor Laboratory Press
DT Journal
LA English
AB Overprodn. of proteins from cloned genes using fusion protein expression
vectors in Escherichia coli and eukaryotic cells has increased the
quantity of protein produced. This approach has been widely used in
producing soluble recombinant proteins for structural and functional anal.
One major disadvantage, however, of applying this approach for clin. or

bioindustrial uses is that proteolytic removal of the fusion carrier is tedious, expensive, and often results in products with addnl. amino acid residues than the native proteins. Here we describe a new method for productions of native proteins with original amino termini in vivo via intracellular self-cleavage of the fusion protein using tobacco etch virus (TEV) protease. Our design allows one to simultaneously clone any gene into multiple fusion protein vectors using two unique cloning sites (i.e., SnaBI and XhoI) without restriction digestion, and then rapidly identifies those constructs producing soluble native proteins. This method will make the fusion protein approach more feasible for protein drug research.
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:875431 CAPLUS
DN 139:359898
TI Reporter-selectable hepatitis C virus replicon and its stably transfected hepatoma cell line for drug screening
IN Duggal, Rohit; Patick, Amy Karen; Zhang, Jie; Zhao, Weidong
PA Pfizer Inc., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091439	A1	20031106	WO 2003-IB1687	20030422

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,

TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2483513	A1	20031106	CA 2003-2483513	20030422
AU 2003225479	A1	20031110	AU 2003-225479	20030422
EP 1499727	A1	20050126	EP 2003-747188	20030422

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005523705	T	20050811	JP 2003-587967	20030422
MX 2004PA10548	A	20050125	MX 2004-PA10548	20041025
PRAI US 2002-375667P	P	20020426		
WO 2003-IB1687	W	20030422		

AB The invention relates to a reporter-selectable hepatitis C virus (HCV) replicon, and use of the replicon to generate stable, human hepatoma cell lines. Specifically, a replicon (BB7-M4-hRLuc) has been constructed containing the 5' NTR fused to a small portion of the core coding region, the humanized Renilla luciferase gene (hRLuc), a self-cleaving peptide of foot and mouth disease virus (FMDV) 2A proteinase, the NPTII gene, and an EMCV IRES (designated EI), followed by the NS3 to NS5B HCV coding region and the 3' NTR region. The replicon has two adaptive mutations in NS3 (E1202G and T1280I) and one in NS5A (S2197P). The stable hepatoma cell line (BB7M4hRLuc#10) stably transfected with this HCV replicon is capable of generating 700,000 relative light units (RLU, units for expressing luciferase activity) of reporter gene activity, which amts. up to a 70 fold difference in signal to noise ratios compared to other available

stable cell line. The replicon and cell lines are useful in the compound
screening process in HCV drug discovery.
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:510609 CAPLUS
DN 125:161813
TI Cloning, expression and purification of HIV-1 protease
AU Wan, Min; Takagi, Masahiro
CS Faculty Medicine, National University Singapore, Singapore
SO Microbial Utilization of Renewable Resources (1996), Volume Date 1995, 9,
348-361
CODEN: MURRE6
PB International Center for Cooperative Research in Biotechnology, Japan
DT Journal
LA English
AB Various constructs containing the N-terminal extended human immunodeficiency
virus type 1 (HIV-1) protease gene (PR 107) were studied. The constructs
of PR 107 gene expressed as fusion protein with the glutathione
S-transferase of the GST gene or the maltose-binding protein (MBP) of the
Mal E gene showed that the full-length fusion protein
exhibited self-processing in E. coli. The results from expts.
indicated that the size of the fusion portion could not affect the
self-processing of HIV-1 protease obviously. Although
the larger fusion portion (MBP) may offer bigger steric-interference for
the formation of the appropriate conformation of the fused
protease and therefore lower the self-cleavage process,
the protease could still easily self-process from the
fusion portion to release itself, despite that only one subunit of the
dimeric protease attached to GST or MBP. An isolation method consisting
of denaturation of protein and followed by refolding was developed for
releasing this recombinant HIV-1 PR into the soluble phase since most of the
expressed protease was initially present in insol. inclusion bodies. More
than 600-fold purification was obtained by sequential purification using Sephadex
G-50 gel filtration and CM-23 cellulose cation exchange chromatog.,

yielding the protease whose purity was more than 95%. SDS-PAGE indicated that the mol. weight of this recombinant HIV-1 PR is 11 kDa. The recombinant HIV-1 protease showed proteolytic activity for the synthetic peptide substrate corresponding to the sequence of gag MA/CA and pol p6*/PR junctions. Immuno-blotting indicated that these recombinant HIV-1 protease specifically reacted with HIV-1 protease antisera. The purified enzyme whose specific activity for the heptapeptide SQNYPIV was 848.7 nmol*min-1*mg protease-1 also processed recombinant polyprotein Gag41 as its substrate.

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:642290 CAPLUS
DN 123:219557
TI Replicating foamy virus-based vectors directing high level expression of foreign genes
AU Schmidt, Michael; Rethwilm, Axel
CS Institut fuer Virologie und Immunbiologie, Universitaet Wuerzburg, Wuerzburg, 97078, Germany
SO Virology (1995), 210(1), 167-78
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic
DT Journal
LA English
AB Replication-competent retroviral vectors (pFOV-1 to -3 and -7) were constructed on the basis of an infectious human foamy virus mol. clone which has deletions in the U3 region of the long terminal repeat and in the 3' region of the genome, previously identified to be nonessential for virus replication in vitro. The CAT and luciferase indicator genes were expressed as C-terminal fusion proteins to 215 amino acids of the viral Bet protein in the pFOV-1 vector. Introduction of the foot-and-mouth disease 2A protease sequence between the truncated bet coding sequence and the cloning site for the insertion of foreign genes in the pFOV-7 vector

resulted in self-cleaving of the recombinant fusion protein. Alternatively, an internal ribosomal binding site was introduced, allowing expression of authentic foreign protein (pFOV-2 and -3 vectors). DNA fragments derived from the mouse hepatitis virus surface gene up to the length of 1.3 kb were inserted into pFOV-1. The vector constructs gave rise to viruses which were fully infectious in diploid human fibroblasts and recombinant viruses stably expressed high levels of foreign protein indicating that the pFOV vectors may be useful tools to study the effects of proteins of interest at least in tissue culture cells.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:576747 CAPLUS
DN 115:176747
TI Self-cleaving fusion proteins
IN Louis, John M.
PA National Institutes of Health, USA
SO U. S. Pat. Appl., 38 pp. Avail. NTIS Order No. PAT-APPL-6-586 079.
CODEN: XAXXAV
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 586079	A0	19910801	US 1990-586079	19900921
US 6077694	A	20000620		
WO 9205276	A1	19920402	WO 1991-US6735	19910920
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9185377	A	19920415	AU 1991-85377	19910920
PRAI US 1990-586079	A	19900921		
WO 1991-US6735	A	19910920		

AB Self-processing fusion proteins are used for the manufacture of a protein of interest. The fusion protein has three domains: an affinity domain for rapid purification of the protein by affinity chromatog.; a retroviral

proteinase domain flanked by cleavage sites recognized by the proteinase;
and, a domain of interest (the target protein). After purification of the
protein by affinity chromatog. the protein is partially denatured allowing
the proteinase to cleave it into three domains. When the fusion protein
is accumulated as inclusion bodies, it may be cleaved during the
denaturation/solubilization process. Use of sequences from the pol region
of the retrovirus gene can be used to control solubility of the protein. The
use of this procedure to purify and accurately cleave soluble and insol.
fusion proteins of human immunodeficiency virus proteinase and the
Escherichia coli malE gene product was demonstrated.

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1039	protease near4 (fusion protein)	US-PGPUB; USPAT	ADJ	OFF	2007/12/20 20:10
L2	83	protease near4 (auto)	US-PGPUB; USPAT	ADJ	OFF	2007/12/20 20:11
L3	6	l1 and l2	US-PGPUB; USPAT	ADJ	OFF	2007/12/20 20:11

See Details. No items found.

Entrez PubMed

Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services

Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources

Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central